No abstract

No abstract

Background: Glioma is one of the most commonly observed tumours, representing about 75% of brain tumours in adult population. Generally, glioma treatment includes surgical resection followed by radiotherapy and chemotherapy. The current chemotherapy for glioma involves use of temozolomide, doxorubicin, monoclonal antibodies, etc. however, the clinical outcomes in patients are not satisfactory. Primarily, blood-brain barrier hinders these drugs from reaching the target leading to the recurrence of glioma post-surgery. In addition, these drugs are not target-specific and affect the healthy cells of the body. Therefore, gliomatargeted drug delivery is essential to reduce the rate of recurrence and treat the condition with more reliable alternatives. Method: Literature search was conducted to understand glioma pathophysiology, its current therapeutic approaches for targeted delivery using databases like Pub Med, Web of science, Scopus, and Google Scholar, etc. Results: This review gives an insight to challenges associated with current treatments, factors influencing drug delivery in glioma, and recent advancements in targeted drug delivery. Conclusion: The promising results could be seen with nanotechnology based approaches, like polymeric, lipid-based and hybrid nanoparticles in treatment of glioma. Biotechnological developments such as carrier peptides and gene therapy are future prospects in glioma therapy. Therefore, these targeted delivery systems will be beneficial in clinical practices for glioma treatment.

No abstract

No abstract